Past Meeting | Keystone Symposia

This meeting took place in the past. Here is a list of meetings that are related:
Drug Discovery for Protozoan Parasites (2012J1)
Drug Discovery for Protozoan Parasites (2009D2)
Drugs Against Protozoan Parasites (2007B1)
Malaria: Functional Genomics to Biology to Medicine (2006C5)
Drugs Against Protozoan Parasites: Target Selection, Structural Biology and Medicinal Chemistry (2005X6)

Web Desc
Drugs Against Tropical Protozoan Parasites: Target Selection, Structural Biology, and Rational Medicinal Chemistry joint with Malaria's Challenge: From Infants to Genomics to Vaccines Organizer(s): Michael H. Gelb and Wim G.J. Hol Date: March 03 - 08, 2002 Location: Keystone Resort, Keystone, CO, USA For important information on the coronavirus, please click here Summary of Meeting: Diseases in humans caused by protozoa lead to suffering in hundreds of millions of people worldwide. We are approaching a time when the genomes of organisms responsible for diseases such as malaria, sleeping sickness, and leishmaniasis are fully sequenced. This provides an optimal setting for the discovery and evaluation of new drug targets, especially when combined with structural biology, combinatorial chemistry, and parasite genetics. Effective drugs are lacking for diseases including sleeping sickness and leishmaniasis, and current therapies for treating malaria are at risk due to the emergence of drug resistance. Thus, the development of new lines of anti-protozoan agents is urgently needed. Groups of talks, one or two given by the chemist/structural biologist and the other by the parasitologist, will exemplify the power of multi-disciplinary collaborations. We will also invite people outside of parasitology in an effort to stimulate their interests in tropical medicine. Discounted Abstract Deadline: November 16 2001 Discounted Registration Deadline: January 3 2002 We gratefully acknowledge the generous grant for this conference provided by: National Institute of Allergy and Infectious Diseases (NIAID) Grant No. 1 R13 AI50962-01 We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising: Click here to view more of these organizations Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds: Click here to view more of these organizations

Web Desc

Drugs Against Tropical Protozoan Parasites: Target Selection, Structural Biology, and Rational Medicinal Chemistry

joint with Malaria's Challenge: From Infants to Genomics to Vaccines

Organizer(s): Michael H. Gelb and Wim G.J. Hol

Date: March 03 - 08, 2002
Location: Keystone Resort, Keystone, CO, USA

For important information on the coronavirus, please click here

Summary of Meeting:

Diseases in humans caused by protozoa lead to suffering in hundreds of millions of people worldwide. We are approaching a time when the genomes of organisms responsible for diseases such as malaria, sleeping sickness, and leishmaniasis are fully sequenced. This provides an optimal setting for the discovery and evaluation of new drug targets, especially when combined with structural biology, combinatorial chemistry, and parasite genetics. Effective drugs are lacking for diseases including sleeping sickness and leishmaniasis, and current therapies for treating malaria are at risk due to the emergence of drug resistance. Thus, the development of new lines of anti-protozoan agents is urgently needed. Groups of talks, one or two given by the chemist/structural biologist and the other by the parasitologist, will exemplify the power of multi-disciplinary collaborations. We will also invite people outside of parasitology in an effort to stimulate their interests in tropical medicine.

Discounted Abstract Deadline: November 16 2001

Discounted Registration Deadline: January 3 2002

We gratefully acknowledge the generous grant for this conference provided by:

National Institute of Allergy and Infectious Diseases (NIAID)
Grant No. 1 R13 AI50962-01

We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations

Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

Program


Sunday, March 03 \| 4:00PM - 7:00PM Registration Room: Shavano Peak Foyer
Sunday, March 03 \| 6:15PM - 7:15PM Welcome Room: Shavano Peak Foyer
Sunday, March 03 \| 7:15PM - 7:30PM Orientation Room: Torreys Peak 3-4
Sunday, March 03 \| 7:30PM - 8:30PM Keynote Address Room: Torreys Peak 3-4 Speaker 1 of 1 David S. Roos, University of Pennsylvania, USA Designing and Mining Parasite Genome Databases
Monday, March 04 \| 7:00AM - 8:00AM Breakfast Room: Red Cloud
Monday, March 04 \| 8:00AM - 11:00AM Impact of Parasite Genomics on Drug Target Selection. Spons ored by The Burroughs Wellcome Fund. Room: Torreys Peak 3-4 Speaker 1 of 6 * Peter J. Myler, Seattle Biomedical Research Institute, USA Kinetoplast Genome Projects
Monday, March 04 \| 8:00AM - 11:00AM Impact of Parasite Genomics on Drug Target Selection. Spons ored by The Burroughs Wellcome Fund. Room: Torreys Peak 3-4 Speaker 2 of 6 Daniel J. Carucci, Foundation for the National Institutes of Health, USA Exploring the Malaria Genome for Targets of Vaccines and Drugs
Monday, March 04 \| 8:00AM - 11:00AM Impact of Parasite Genomics on Drug Target Selection. Spons ored by The Burroughs Wellcome Fund. Room: Torreys Peak 3-4 Speaker 3 of 6 Terry Gaasterland, University of California, San Diego, USA Computational Analysis of the Trypanosoma brucei Genome
Monday, March 04 \| 8:00AM - 11:00AM Impact of Parasite Genomics on Drug Target Selection. Spons ored by The Burroughs Wellcome Fund. Room: Torreys Peak 3-4 Speaker 4 of 6 Stephen M. Beverley, Washington University School of Medicine, USA Molecular Approaches to Trypanosomatid Pteridine Metabolic Pathways and Their Role(s) in Virulence and Chemotherapy
Monday, March 04 \| 8:00AM - 11:00AM Impact of Parasite Genomics on Drug Target Selection. Spons ored by The Burroughs Wellcome Fund. Room: Torreys Peak 3-4 Speaker 5 of 6 Sebastian Ulbert, Netherlands Cancer Institute, Netherlands Short Talk: The Significance of Base J in the DNA of Trypanosoma brucei for the Base Excision Repair
Monday, March 04 \| 8:00AM - 11:00AM Impact of Parasite Genomics on Drug Target Selection. Spons ored by The Burroughs Wellcome Fund. Room: Torreys Peak 3-4 Speaker 6 of 6 Christian Doerig, Monash University, Australia Short Talk: A Chemical Genetics Approach for Functional Studies and Target Validation of Plasmodium Protein Kinases
Monday, March 04 \| 8:00AM - 11:00AM Defining the Malaria Problem and the Human Models Indicating Developing Vaccines is Feasible This session is from Malaria's Challenge Room: Torreys Peak1-2 Speaker 1 of 5 * Louis H. Miller, National Institutes of Health, USA
Monday, March 04 \| 8:00AM - 11:00AM Defining the Malaria Problem and the Human Models Indicating Developing Vaccines is Feasible This session is from Malaria's Challenge Room: Torreys Peak1-2 Speaker 2 of 5 Kevin Marsh, University of Oxford, Kenya Malaria Vaccination: What are We Trying to Prevent?
Monday, March 04 \| 8:00AM - 11:00AM Defining the Malaria Problem and the Human Models Indicating Developing Vaccines is Feasible This session is from Malaria's Challenge Room: Torreys Peak1-2 Speaker 3 of 5 Stephen L. Hoffman, Sanaria, USA Induction of Protection Against Malaria in Naïve Humans by Experimental Exposure to Whole Parasites
Monday, March 04 \| 8:00AM - 11:00AM Defining the Malaria Problem and the Human Models Indicating Developing Vaccines is Feasible This session is from Malaria's Challenge Room: Torreys Peak1-2 Speaker 4 of 5 Andrew G. Clark, Cornell University, USA The Role of Population Biology and Genetics in Developing Strategies for Malaria Vaccine Development
Monday, March 04 \| 8:00AM - 11:00AM Defining the Malaria Problem and the Human Models Indicating Developing Vaccines is Feasible This session is from Malaria's Challenge Room: Torreys Peak1-2 Speaker 5 of 5 Andrew Read, Pennsylvania State University, USA Imperfect Vaccines and the Evolution of Virulence
Monday, March 04 \| 9:20AM - 9:40AM Coffee Break Room: Shavano Peak Foyer
Monday, March 04 \| 11:00AM - 1:00PM Poster Setup Room: Shavano Peak
Monday, March 04 \| 1:00PM - 10:00PM Poster Viewing Room: Shavano Peak
Monday, March 04 \| 4:30PM - 5:00PM Coffee & Snacks Available Room: Shavano Peak Foyer
Monday, March 04 \| 5:00PM - 7:00PM Target Selection and Drug Development-I Room: Torreys Peak 3-4 Speaker 1 of 4 * Daniel E. Goldberg, Washington University, USA The Biochemistry of Hemoglobin Digestion in P. falciparum
Monday, March 04 \| 5:00PM - 7:00PM Target Selection and Drug Development-I Room: Torreys Peak 3-4 Speaker 2 of 4 Gary H. Posner, Johns Hopkins University, USA Mechanism-Based Rational Design of New Antimalarial Peroxides
Monday, March 04 \| 5:00PM - 7:00PM Target Selection and Drug Development-I Room: Torreys Peak 3-4 Speaker 3 of 4 James H. McKerrow, University of California, San Diego, USA Inhibitors of Thiol Proteases for Treating Chagas Disease
Monday, March 04 \| 5:00PM - 7:00PM Target Selection and Drug Development-I Room: Torreys Peak 3-4 Speaker 4 of 4 Akhil B. Vaidya, Drexel University College of Medicine, USA Selective Interference with Parasite Mitochondrial Functions
Monday, March 04 \| 5:00PM - 7:00PM Genes, Genomics and Malaria. Session Sponsored by The Burro ughs Wellcome Fund This session is from Malaria's Challenge Room: Torreys Peak 1-2 Speaker 1 of 4 * Victor Nussenzweig, New York University, USA
Monday, March 04 \| 5:00PM - 7:00PM Genes, Genomics and Malaria. Session Sponsored by The Burro ughs Wellcome Fund This session is from Malaria's Challenge Room: Torreys Peak 1-2 Speaker 2 of 4 Louis H. Miller, National Institutes of Health, USA Genes Involved in Susceptibility to Malaria
Monday, March 04 \| 5:00PM - 7:00PM Genes, Genomics and Malaria. Session Sponsored by The Burro ughs Wellcome Fund This session is from Malaria's Challenge Room: Torreys Peak 1-2 Speaker 3 of 4 Ross L. Coppel, Monash University, Australia How is the Malaria Genome Facilitating Studies on Malaria?
Monday, March 04 \| 5:00PM - 7:00PM Genes, Genomics and Malaria. Session Sponsored by The Burro ughs Wellcome Fund This session is from Malaria's Challenge Room: Torreys Peak 1-2 Speaker 4 of 4 Mani Subramanian, Celera Genomics, USA The Potential Impact of the Human Genome Project on Malaria and Other Infectious Diseases
Monday, March 04 \| 7:00PM - 8:00PM Welcome Mixer Room: Shavano Peak
Monday, March 04 \| 7:00PM - 9:00PM Cash Bar Room: Shavano Peak
Monday, March 04 \| 8:00PM - 10:00PM Poster Session 1: Impact of Parasite Genomics on Drug Target Selection/Target Selection and Drug Development Room: Shavano Peak
Tuesday, March 05 \| 7:00AM - 8:00AM Breakfast Room: Red Cloud
Tuesday, March 05 \| 8:00AM - 11:00AM Structure-Based Drug Design Room: Torreys Peak 3-4 Speaker 1 of 6 * Gerhard Klebe, Philipps University Marburg, Germany New Leads from De Novo Design and Virtual Screening for the Treatment of Shigellosis and Malaria
Tuesday, March 05 \| 8:00AM - 11:00AM Structure-Based Drug Design Room: Torreys Peak 3-4 Speaker 2 of 6 William T. Windsor, Schering-Plough Research Institute, USA Structure Based Design of Protein Farnesyltransferase Inhibitors
Tuesday, March 05 \| 8:00AM - 11:00AM Structure-Based Drug Design Room: Torreys Peak 3-4 Speaker 3 of 6 William N. Hunter, University of Dundee, UK X-ray Studies of Trypanothione Reductase; The Discovery of Novel Inhibitors
Tuesday, March 05 \| 8:00AM - 11:00AM Structure-Based Drug Design Room: Torreys Peak 3-4 Speaker 4 of 6 Timothy A.J. Haystead, Duke University, USA Discovery of a New Antimilarial Target in the Human Purine Binding Proteome
Tuesday, March 05 \| 8:00AM - 11:00AM Structure-Based Drug Design Room: Torreys Peak 3-4 Speaker 5 of 6 Vern L. Schramm, Albert Einstein College of Medicine, USA Short Talk: Inhibition of PNP by Immucillins Induces Purine-Less Death of Plasmodium falciparum in Cultured Erythrocytes
Tuesday, March 05 \| 8:00AM - 11:00AM Structure-Based Drug Design Room: Torreys Peak 3-4 Speaker 6 of 6 Meg Phillips, University of Texas Southwestern Medical Center, USA Short Talk: Interactions in the Dimer Interface of Trypanosoma brucei Ornithine Decarboxylase: Implications for Drug Design
Tuesday, March 05 \| 8:00AM - 11:00AM Immunological Mechanisms of Protective Immunity This session is from Malaria's Challenge Room: Torreys Peak 1-2 Speaker 1 of 5 * † Martha Sedegah, Naval Medical Research Center, USA
Tuesday, March 05 \| 8:00AM - 11:00AM Immunological Mechanisms of Protective Immunity This session is from Malaria's Challenge Room: Torreys Peak 1-2 Speaker 2 of 5 Eleanor M. Riley, Roslin Institute, UK Regulation of Innate and Adaptive Immunity to Malaria in Humans
Tuesday, March 05 \| 8:00AM - 11:00AM Immunological Mechanisms of Protective Immunity This session is from Malaria's Challenge Room: Torreys Peak 1-2 Speaker 3 of 5 Denise L. Doolan, James Cook University, Australia Immunological Mechanisms of Protective Immunity Induced by Radiation Attenuated Sporozoites
Tuesday, March 05 \| 8:00AM - 11:00AM Immunological Mechanisms of Protective Immunity This session is from Malaria's Challenge Room: Torreys Peak 1-2 Speaker 4 of 5 Allan J. Saul, National Institutes Of Health, USA Nature and Immunologic Mechanisms of Protective Immunity Against Mosquito Stage Parasites
Tuesday, March 05 \| 8:00AM - 11:00AM Immunological Mechanisms of Protective Immunity This session is from Malaria's Challenge Room: Torreys Peak 1-2 Speaker 5 of 5 Michael F. Good, Griffith University, Australia Short Talk: Induction of Malaria Cell Mediated Immunity and Target Antigen Identification
Tuesday, March 05 \| 9:20AM - 9:40AM Coffee Break Room: Shavano Peak Foyer
Tuesday, March 05 \| 11:00AM - 1:00PM Poster Setup Room: Shavano Peak
Tuesday, March 05 \| 1:00PM - 10:00PM Poster Viewing Room: Shavano Peak
Tuesday, March 05 \| 2:30PM - 4:30PM Open Discussion: Are We Missing Something? Why is it Taking So Long to Develop Effective Malaria Vaccines? This session is from Malaria's Challenge Room: Torreys Peak 1-2
Tuesday, March 05 \| 4:30PM - 5:00PM Coffee & Snacks Available Room: Shavano Peak Foyer
Tuesday, March 05 \| 5:00PM - 7:00PM Target Selection and Drug Development-II Room: Torreys Peak 3-4 Speaker 1 of 4 * Richard R. Tidwell, University of North Carolina at Chapel Hill, USA Pentamidine-Type Compounds as Antiprotozoan Agents. Contemporary Investigations of these Molecules.
Tuesday, March 05 \| 5:00PM - 7:00PM Target Selection and Drug Development-II Room: Torreys Peak 3-4 Speaker 2 of 4 Henri Vial, Universite Montpellier II, France Peculiarities of the Phospholipid Metabolism in the Malaria-Causing Parasite Plasmodium and Pharmacological Implications
Tuesday, March 05 \| 5:00PM - 7:00PM Target Selection and Drug Development-II Room: Torreys Peak 3-4 Speaker 3 of 4 Philip J. Rosenthal, University of California, San Francisco, USA Cysteine Protease Inhibitors to Treat Malaria
Tuesday, March 05 \| 5:00PM - 7:00PM Target Selection and Drug Development-II Room: Torreys Peak 3-4 Speaker 4 of 4 Frederick S. Buckner, University of Washington, USA Sterol Biosynthesis and Protein Prenylation Pathways as Targets for Anti-Protozoan Chemotherapy
Tuesday, March 05 \| 5:00PM - 7:00PM Identifying the Antigenic Targets (Proteins and Epitopes) of Protective Immune Responses. Session Sponsored by Science Applications International Corp. (SAIC) This session is from Malaria's Challenge Room: Torreys Peak 1-2 Speaker 1 of 5 * † Robin Fredric Anders, La Trobe University, Australia
Tuesday, March 05 \| 5:00PM - 7:00PM Identifying the Antigenic Targets (Proteins and Epitopes) of Protective Immune Responses. Session Sponsored by Science Applications International Corp. (SAIC) This session is from Malaria's Challenge Room: Torreys Peak 1-2 Speaker 2 of 5 Anthony A. Holder, Medical Research Council, UK Antibodies to Merozoite Surface Proteins and Inhibition of Erythrocyte Invasion
Tuesday, March 05 \| 5:00PM - 7:00PM Identifying the Antigenic Targets (Proteins and Epitopes) of Protective Immune Responses. Session Sponsored by Science Applications International Corp. (SAIC) This session is from Malaria's Challenge Room: Torreys Peak 1-2 Speaker 3 of 5 Alessandro Sette, La Jolla Institute for Immunology, USA The Multi-Epitope Approach to Development of Malaria Vaccine
Tuesday, March 05 \| 5:00PM - 7:00PM Identifying the Antigenic Targets (Proteins and Epitopes) of Protective Immune Responses. Session Sponsored by Science Applications International Corp. (SAIC) This session is from Malaria's Challenge Room: Torreys Peak 1-2 Speaker 4 of 5 Daniel J. Carucci, Foundation for the National Institutes of Health, USA Exploring the Malaria Genome for Targets of Vaccines and Drugs
Tuesday, March 05 \| 5:00PM - 7:00PM Identifying the Antigenic Targets (Proteins and Epitopes) of Protective Immune Responses. Session Sponsored by Science Applications International Corp. (SAIC) This session is from Malaria's Challenge Room: Torreys Peak 1-2 Speaker 5 of 5 Patrick E. Duffy, NIAID, National Institutes for Health, USA Variant Surface Antigens on Infected Erythrocytes: Vaccine Prospects
Tuesday, March 05 \| 7:00PM - 8:00PM Welcome Mixer Room: Shavano Peak
Tuesday, March 05 \| 7:00PM - 9:00PM Cash Bar Room: Shavano Peak
Tuesday, March 05 \| 8:00PM - 10:00PM Poster Session 2: Structure-Based Drug Design/Target Selecti on and Drug Development Room: Shavano Peak
Wednesday, March 06 \| 7:00AM - 8:00AM Breakfast Room: Red Cloud
Wednesday, March 06 \| 8:00AM - 11:00AM Target Selection, Drug Resistance Room: Torreys Peak 3-4 Speaker 1 of 6 * Paul A.M. Michels, Christian de Duve Institute of Cellular Pathology, Belgium Glycosomes of Trypanosomes as Target for Drug Design
Wednesday, March 06 \| 8:00AM - 11:00AM Target Selection, Drug Resistance Room: Torreys Peak 3-4 Speaker 2 of 6 Aloysius G.M. Tielens, University of Utrecht, Netherlands Mitochondrial Metabolism as Possible Drug Target?
Wednesday, March 06 \| 8:00AM - 11:00AM Target Selection, Drug Resistance Room: Torreys Peak 3-4 Speaker 3 of 6 Pradipsinh K. Rathod, University of Washington, USA Initiation of Malaria Drug Resistance Through Hypermutations
Wednesday, March 06 \| 8:00AM - 11:00AM Target Selection, Drug Resistance Room: Torreys Peak 3-4 Speaker 4 of 6 Dyann F. Wirth, Harvard School of Public Health, USA Molecular Genetics of Leishmania and Plasmodium: Implications for Drug Discovery and Drug Resistance
Wednesday, March 06 \| 8:00AM - 11:00AM Target Selection, Drug Resistance Room: Torreys Peak 3-4 Speaker 5 of 6 David C. Warhurst, London School of Hygiene and Tropical Medicine, UK Short Talk: Understanding Drug-Resistance of Plasmodium falciparum DHFR by Homology Modeling
Wednesday, March 06 \| 8:00AM - 11:00AM Target Selection, Drug Resistance Room: Torreys Peak 3-4 Speaker 6 of 6 Jeanne A. Geyer, Walter Reed Army Institute of Research, USA Short Talk: Drug Treatment and Genomic Stability in Plasmodium falciparum
Wednesday, March 06 \| 8:00AM - 11:00AM Pre-Clinical Research and Development This session is from Malaria's Challenge Room: Torreys Peak 1-2 Speaker 1 of 1 * Rafi Ahmed, Emory University School of Medicine, USA Vaccines and Immune Memory
Wednesday, March 06 \| 8:30AM - 9:30AM Rountable: How Does One Optimize the Magnitude, Quality, and Longevity of T Cell Responses in Humans? This session is from Malaria's Challenge Speaker 1 of 2 * Stephen L. Hoffman, Sanaria, USA
Wednesday, March 06 \| 8:30AM - 9:30AM Rountable: How Does One Optimize the Magnitude, Quality, and Longevity of T Cell Responses in Humans? This session is from Malaria's Challenge Speaker 2 of 2 * Adrian V. S. Hill, Jenner Institute, University of Oxford, UK
Wednesday, March 06 \| 9:20AM - 9:40AM Coffee Break Room: Shavano Peak Foyer
Wednesday, March 06 \| 9:30AM - 11:00AM Pre-Clinical Research and Development This session is from Malaria's Challenge Speaker 1 of 2 Garnett H. Kelsoe, Duke University and Medical Center, USA Infection, Inflammation and the Induction of Peripheral V(D)J Rearrangement
Wednesday, March 06 \| 9:30AM - 11:00AM Pre-Clinical Research and Development This session is from Malaria's Challenge Speaker to be Announced Applied Perspective: How Does One Optimize the Magnitude, Quality, and Duration of B Cell Responses?
Wednesday, March 06 \| 11:00AM - 1:00PM Poster Setup Room: Shavano Peak
Wednesday, March 06 \| 1:00PM - 10:00PM Poster Viewing Room: Shavano Peak
Wednesday, March 06 \| 4:30PM - 5:00PM Coffee & Snacks Available Room: Shavano Peak Foyer
Wednesday, March 06 \| 5:00PM - 7:00PM Target Selection and Drug Development-III Room: Torreys Peak 3-4 Speaker 1 of 4 * Donald J. Krogstad, Tulane University Health Sciences Center, USA Aminoquinoline Antimalarials Active Against Multiply-Resistant P. falciparum
Wednesday, March 06 \| 5:00PM - 7:00PM Target Selection and Drug Development-III Room: Torreys Peak 3-4 Speaker 2 of 4 Dennis M. Schmatz, Merck Research Laboratories, USA The Drug Discovery Process: A Pharmaceutical Perspective
Wednesday, March 06 \| 5:00PM - 7:00PM Target Selection and Drug Development-III Room: Torreys Peak 3-4 Speaker 3 of 4 Buddy Ullman, Oregon Health & Science University, USA Nucleoside Transporters of Protozoan Parasites
Wednesday, March 06 \| 5:00PM - 7:00PM Target Selection and Drug Development-III Room: Torreys Peak 3-4 Speaker 4 of 4 Wim G.J. Hol, University of Washington, USA Medicinal Protein Crystallography and Structural Genomics for Tropical Diseases
Wednesday, March 06 \| 5:00PM - 7:00PM Pre-Clinical Development and Clinical Testing This session is from Malaria's Challenge Room: Torreys Peak 1-2 Speaker 1 of 4 * † Chetan E. Chitnis, International Centre for Genetic Engineering and Biotechnology, India
Wednesday, March 06 \| 5:00PM - 7:00PM Pre-Clinical Development and Clinical Testing This session is from Malaria's Challenge Room: Torreys Peak 1-2 Speaker 2 of 4 Ruth S. Nussenzweig, New York University School of Medicine, USA Special Lecture: From Rodents to Humans: 35 Years of Malaria Vaccine Development
Wednesday, March 06 \| 5:00PM - 7:00PM Pre-Clinical Development and Clinical Testing This session is from Malaria's Challenge Room: Torreys Peak 1-2 Speaker 3 of 4 Carole A. Long, National Institutes of Health, USA Laboratory Correlates of in vivo Protective Responses
Wednesday, March 06 \| 5:00PM - 7:00PM Pre-Clinical Development and Clinical Testing This session is from Malaria's Challenge Room: Torreys Peak 1-2 Speaker 4 of 4 Pedro L. Alonso, World Health Organization, Switzerland Field Trials of Malaria Vaccines
Wednesday, March 06 \| 7:00PM - 7:45PM Roundtable: Outcome Variables for Clinical Trials This session is from Malaria's Challenge Room: Torreys Peak 1-2 Speaker 1 of 2 * Pedro L. Alonso, World Health Organization, Switzerland
Wednesday, March 06 \| 7:00PM - 7:45PM Roundtable: Outcome Variables for Clinical Trials This session is from Malaria's Challenge Room: Torreys Peak 1-2 Speaker 2 of 2 * † Kwadwo Ansah Koram, Noguchi Memorial Institute for Medical Research, Ghana
Wednesday, March 06 \| 7:00PM - 8:00PM Welcome Mixer Room: Shavano Peak
Wednesday, March 06 \| 7:00PM - 9:00PM Cash Bar Room: Shavano Peak
Wednesday, March 06 \| 8:00PM - 10:00PM Poster Session 3: Target Selection, Drug Resistance/Target S election and Drug Development Room: Shavano Peak
Thursday, March 07 \| 7:00AM - 8:00AM Breakfast Room: Red Cloud
Thursday, March 07 \| 8:00AM - 11:00AM Target Selection and Drug Development-IV Room: Torreys Peak 3-4 Speaker 1 of 6 * Michael Riscoe, Oregon Health & Science University, USA Exploitation of Parasite Heme Metabolism by Xanthones
Thursday, March 07 \| 8:00AM - 11:00AM Target Selection and Drug Development-IV Room: Torreys Peak 3-4 Speaker 2 of 6 Nicholas J. Westwood, University of St Andrews, UK Chemical Genetic Approaches in Parasitology
Thursday, March 07 \| 8:00AM - 11:00AM Target Selection and Drug Development-IV Room: Torreys Peak 3-4 Speaker 3 of 6 Andrew D. Hamilton, Yale University, USA Protein Farnesyltransferase as a Novel Target for the Design of Anti-Parasitic Agents
Thursday, March 07 \| 8:00AM - 11:00AM Target Selection and Drug Development-IV Room: Torreys Peak 3-4 Speaker 4 of 6 Sanjeev Krishna, St. George's Hospital Medical School, UK The Plasmodium Falciparum Hexose Transporter is a Promising New Drug Target
Thursday, March 07 \| 8:00AM - 11:00AM Target Selection and Drug Development-IV Room: Torreys Peak 3-4 Speaker 5 of 6 Eric Oldfield, University of Illinois at Urbana-Champaign, USA Short Talk: Prenyl Diphosphate Synthase Inhibitors as Anti-Parasitic Agents
Thursday, March 07 \| 8:00AM - 11:00AM Target Selection and Drug Development-IV Room: Torreys Peak 3-4 Speaker 6 of 6 Norman C. Waters, United States Military Academy, USA Short Talk: Targeting the Plasmodial Cell Cycle Machinery Through Development of Novel Cyclin Dependent Protein Kinase Inhibitors
Thursday, March 07 \| 8:00AM - 11:00AM Current Status of Efficacy Trials of Malaria Vaccines. Sess ion Sponsored by GlaxoSmithKline Biologicals S.A. This session is from Malaria's Challenge Room: Torreys Peak 1-2 Speaker 1 of 5 * † Joe D. Cohen, GlaxoSmithKline Biologicals, Belgium
Thursday, March 07 \| 8:00AM - 11:00AM Current Status of Efficacy Trials of Malaria Vaccines. Sess ion Sponsored by GlaxoSmithKline Biologicals S.A. This session is from Malaria's Challenge Room: Torreys Peak 1-2 Speaker 2 of 5 D. Gray Heppner, Walter Reed Army Institute of Research, USA Current Status of Clinical Trials with RTS, S and MSP-1 and AMA-1 Recombinant Protein Vaccines
Thursday, March 07 \| 8:00AM - 11:00AM Current Status of Efficacy Trials of Malaria Vaccines. Sess ion Sponsored by GlaxoSmithKline Biologicals S.A. This session is from Malaria's Challenge Room: Torreys Peak 1-2 Speaker 3 of 5 Thomas L. Richie, Sanaria Inc., USA Clinical Trials of Multi-Stage DNA Malaria Vaccines
Thursday, March 07 \| 8:00AM - 11:00AM Current Status of Efficacy Trials of Malaria Vaccines. Sess ion Sponsored by GlaxoSmithKline Biologicals S.A. This session is from Malaria's Challenge Room: Torreys Peak 1-2 Speaker 4 of 5 Adrian V. S. Hill, Jenner Institute, University of Oxford, UK Clinical Trials of Protective T Cell Inducing Vaccines
Thursday, March 07 \| 8:00AM - 11:00AM Current Status of Efficacy Trials of Malaria Vaccines. Sess ion Sponsored by GlaxoSmithKline Biologicals S.A. This session is from Malaria's Challenge Room: Torreys Peak 1-2 Speakers to be Announced Short Updates from Other Speakers on Their Clinical Trials
Thursday, March 07 \| 9:20AM - 9:40AM Coffee Break Room: Shavano Peak Foyer
Thursday, March 07 \| 4:00PM - 5:00PM Coffee & Snacks Available Room: Shavano Peak Foyer
Thursday, March 07 \| 4:00PM - 6:00PM Target Selection and Drug Development-V Room: Torreys Peak 3-4 Speaker 1 of 4 * Julio A. Urbina, Venezuelan Institute for Science Research, USA Isoprenoid and Sterol Biosynthesis Enzymes as Chemotherapeutic Targets in Trypanosomatid Parasites: Chemical Validation
Thursday, March 07 \| 4:00PM - 6:00PM Target Selection and Drug Development-V Room: Torreys Peak 3-4 Speaker 2 of 4 Glaucius Oliva, University of São Paulo, Brazil Rational Design and Biodiversity in the Search of New Anti-Chagasic Drugs
Thursday, March 07 \| 4:00PM - 6:00PM Target Selection and Drug Development-V Room: Torreys Peak 3-4 Speaker 3 of 4 Ching-Chung Wang, University of California, San Francisco, USA The Presence of an Essential Ubiquitin-Proteasome Pathway in Trypanosoma brucei
Thursday, March 07 \| 4:00PM - 6:00PM Target Selection and Drug Development-V Room: Torreys Peak 3-4 Speaker 4 of 4 Jeremy C. Mottram, University of Glasgow, UK Unusual Cysteine Proteases as Drug Targets in Trypanosomatids
Thursday, March 07 \| 5:00PM - 7:00PM From Research to Deployed Malaria Vaccine This session is from Malaria's Challenge Room: Torreys Peak 1-2 Speaker 1 of 3 * † Robert Sauerwein, Radboud University, Netherlands
Thursday, March 07 \| 5:00PM - 7:00PM From Research to Deployed Malaria Vaccine This session is from Malaria's Challenge Room: Torreys Peak 1-2 Speaker 2 of 3 Regina N. Rabinovich, ISGlobal, Spain / Harvard T.H. Chan School of Public Health, USA, Spain Is Current Investment Adequate Enough to Develop a Potential Malaria Vaccine?
Thursday, March 07 \| 5:00PM - 7:00PM From Research to Deployed Malaria Vaccine This session is from Malaria's Challenge Room: Torreys Peak 1-2 Speakers to be Announced Discussion Group
Thursday, March 07 \| 6:00PM - 7:00PM Plenary Speaker 1 of 3 Simon L. Croft, London School of Hygiene & Tropical Medicine, UK Short Talk: Miltefosine for the Treatment of Leishmaniasis
Thursday, March 07 \| 6:00PM - 7:00PM Plenary Speaker 2 of 3 Solomon O. Nwaka, World Health Organization, Switzerland Short Talk: Medicines for Malaria Venture: New Paradigm for the Discovery and Development of Antimalarial Drugs
Thursday, March 07 \| 6:00PM - 7:00PM Plenary Speaker 3 of 3 Victoria G. Hale, Institute for OneWorld Health, USA Short Talk: The Institute for One World Health: Filling the Gaps in the Development of New Drugs for Neglected Diseases
Thursday, March 07 \| 7:00PM - 8:00PM Welcome Mixer Room: Shavano Peak
Thursday, March 07 \| 8:00PM - 11:00PM Entertainment Room: Shavano Peak
Thursday, March 07 \| 8:00PM - 11:00PM Cash Bar Room: Shavano Peak
Friday, March 08 \| 10:21AM - 10:21AM Departure *Session Chair †Invited, not yet responded.